These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 6777463)

  • 1. Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.
    Schachter M; Marsden CD; Parkes JD; Jenner P; Testa B
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1016-21. PubMed ID: 6777463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease.
    Presthus J; Hajba A
    Acta Neurol Scand Suppl; 1983; 95():127-33. PubMed ID: 6428145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Birkmayer W
    Acta Neurol Scand Suppl; 1983; 95():103-5. PubMed ID: 6428140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline (1-deprenyl) and low-dose levodopa treatment of Parkinson's disease. A double-blind crossover trial.
    Presthus J; Berstad J; Lien K
    Acta Neurol Scand; 1987 Sep; 76(3):200-3. PubMed ID: 3120487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deprenyl (selegiline) in the treatment of Parkinson's disease.
    Rinne UK
    Acta Neurol Scand Suppl; 1983; 95():107-11. PubMed ID: 6428141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease.
    Golbe LI; Lieberman AN; Muenter MD; Ahlskog JE; Gopinathan G; Neophytides AN; Foo SH; Duvoisin RC
    Clin Neuropharmacol; 1988 Feb; 11(1):45-55. PubMed ID: 3127050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline as an adjunct to conventional levodopa therapy in Parkinson's disease. Experience with this type B monoamine oxidase inhibitor in 200 patients.
    Elizan TS; Yahr MD; Moros DA; Mendoza MR; Pang S; Bodian CA
    Arch Neurol; 1989 Dec; 46(12):1280-3. PubMed ID: 2511825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contribution of amphetamine metabolites of (-)-deprenyl to its antiparkinsonian properties.
    Elsworth JD; Sandler M; Lees AJ; Ward C; Stern GM
    J Neural Transm; 1982; 54(1-2):105-10. PubMed ID: 6809891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deprenyl (selegiline) in combination treatment of Parkinson's disease.
    Gerstenbrand F; Ransmayr G; Poewe W
    Acta Neurol Scand Suppl; 1983; 95():123-6. PubMed ID: 6428144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deprenyl in Parkinson's disease.
    Lees AJ; Shaw KM; Kohout LJ; Stern GM; Elsworth JD; Sandler M; Youdim MB
    Lancet; 1977 Oct; 2(8042):791-5. PubMed ID: 71602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (-)Deprenyl in the treatment of decompensated Parkinson's disease.
    Csanda E; Tárczy M; Takáts A
    J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor.
    Przuntek H; Kuhn W
    J Neural Transm Suppl; 1987; 25():97-104. PubMed ID: 3123607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients.
    Streifler M; Rabey MJ
    J Neural Transm Suppl; 1983; 19():265-72. PubMed ID: 6421992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline in the treatment of Parkinson's disease.
    Heinonen EH; Rinne UK
    Acta Neurol Scand Suppl; 1989; 126():103-11. PubMed ID: 2515715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selegiline and levodopa in early or moderately advanced Parkinson's disease: a double-blind controlled short- and long-term study.
    Sivertsen B; Dupont E; Mikkelsen B; Mogensen P; Rasmussen C; Boesen F; Heinonen E
    Acta Neurol Scand Suppl; 1989; 126():147-52. PubMed ID: 2515720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease.
    Csanda E; Tárczy M
    Acta Neurol Scand Suppl; 1983; 95():117-22. PubMed ID: 6428143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.